General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal’s scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the International Institute of Anticancer Research (IIAR) and is available online with Stanford University HighWire Press. The IIAR is a member of UICC. For more information please visit our website www.cgp.iiarjournals.org.

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org
**ANTICANCER RESEARCH** is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

**ANTICANCER RESEARCH** is published monthly by the International Institute of Anticancer Research and is available online with Stanford University HighWire Press. The IIAR is a member of UICC.

**Editorial Office:** International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

**Selection of Recent Articles**

Inhibition of Galectin-1 Sensitizes HRAS-driven Tumor Growth to Rapamycin Treatment. J.V. MICHAEL, J.G.T. WURTZEL, L.E. GOLDFINGER (Philadelphia, PA, USA)

In Vivo Selection of Intermediately and Highly Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models. S. YANO, K. TAKEHARA, H. KISHIMOTO, H. TAZAWA, Y. URATA, S. KAGAWA, M. BOUVET, T. FUJIWARA, R.M. HOFFMAN (San Diego, CA, USA; Okayama; Tokyo, Japan)

A Single Intravesical Instillation of VAX014 Inhibits Orthotopic Superficial Bladder Tumor Implantation to Increase Survival. B.M. HANCOCK, K.L. MCGUIRE, S. TSUI, K. REIL, V. HERNANDEZ, M.J. GIACALONE, W.T. GODBEE (San Diego, CA; New Orleans, LA, USA)

Beverizumab Combined with Docetaxel or Paclitaxel as First-line treatment of HER2-negative Metastatic Breast Cancer. L. TIAIEN, M. TANNER, O. LAHDENPERÄ, P. VIHINE, A. JUKKOLA, P. KARIHTALA, N. PAUNU, T. HUTTUNEN, P.-L. KELLOKUMPU-LEHTINEN (Tampere; Turku; Oulu, Finland)

Plasma Adiponectin and Hepatocellular Carcinoma Survival among Patients without Liver Transplantation. J. SHEN, C.-C. YEH, Q. WANG, I. GURVICH, A.B. SIEGEL, R.M. SANTELLO (New York, NY, USA; Taipei, Taiwan, ROC)

Y-box-binding Protein 1 is Involved in Regulating the G2/M Phase of the Cell Cycle. Y. KOTAKE, N. ARIKAWA, K. TAHARA, H. MARU, M. NAEMURA (Izuka, Japan)

Cervical Cancer Patient-Derived Orthotopic Xenograft (PDXO) is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel. T. MURAKAMI, T. MURATA, K. KAWAGUCHI, T. KIYUNA, K. IGARASHI, H.K. HWANG, Y. HIROSHIMA, C. HOZUMI, S. KOMATSU, T. KIKUCHI, T.M. LWIN, J.C. DELONG, K. MIYAKE, Y. ZHANG, K. TANAKA, M. BOUVET, I. ENDO, R.M. HOFFMAN (San Diego, CA, USA; Yokohama; Okayama; Sendai; Okinawa; Kanazawa; Tokyo, Japan; Seoul, Republic of Korea)

Different Expression Patterns of CXCR4, CCR7, Maspin and FOXP3 in Luminal Breast Cancers and Their Sentinel Node Metastases. L. STRIEN, K. JOENSSU, P. HEIKKILÄ, M.H. LEIDENIUS (Helsinki, Finland)

KIF11 Is Required for Spheroid Formation by Oesophageal and Colorectal Cancer Cells. T. IMAI, N. OUE, K. SENTANI, N. SAKAMOTO, N. URAOKA, H. EGI, T. HINOI, H. OHNAN, K. YASUI (Hiroshima; Gifu; Kure, Japan)

11C-Acetate-PET/CT Compared to 99mTc-HDP Bone Scintigraphy in Primary Staging of High-risk Prostate Cancer. S. STRANDBERG, C. HELLENBERG KARLSSON, M. OGREN, J. AXELSSON, K. RIKLUND (Umea, Sweden)

Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens. I. OKAZAKI, S. ISHIKAWA, W. ANDO, Y. SOHARA (Tokyo; Otawara; Okegawa, Japan)

Epithelial–Mesenchymal Expression Phenotype of Primary Melanoma and Matched Metastases and Relationship with Overall Survival. S. YAN, B.M. HOLDERNESS, Z. LI, G.D. SEIDEL, J. GUI, J.L. FISHER, M.S. ERNSTOFT (Lebanon, NH; Buffalo, NY, USA)

Kinomics Screen Identifies Aberrant Phosphorylation of CDC25C in FLT3-ITD-positive AML. F. PERNER, T.M. SCHNÖDER, T. FISCHER, F.H. HEIDEL (Magdeburg; Jena, Germany)

Ectopic Myoglobin Expression is Associated with a Favourable Outcome in Head and Neck Squamous Cell Carcinoma Patients. S. MELLER, A. VAN ELLEN, H. GEVENSLEBEN, A. BICKER, T. HANKELN, T.A. GORR, V. SAILE, F. DROGE, F. SCHRÖCK, F. BOOTZ, A. SCHÖCK, S. PERNER, D. DIETRICH, G. KRISTIANSEN (Mainz; Bonn; Essen; Luebeck and Borstel, Germany; Zurich, Switzerland; New York, NY, USA)

**ISSN (print):** 0250-7005; **ISSN (online):** 1791-7530

FREE SPECIMEN COPIES OF ANTICANCER RESEARCH ARE AVAILABLE ON REQUEST
Effects of Caspase 9 Gene Polymorphism in Patients with Prostate Cancer. S.G. YILMAZ, F. YENCILEK, A. YILDIRIM, E. YENCILEK, T. ISBIR (*Istanbul, Turkey*) ................................................................. 205

The Effect of Geraniol on Liver Regeneration After Hepatectomy in Rats. M. CANBEK, M. UYANOGLU, S. CANBEK, E. CEYHAN, A. OZEN, B. DURMUS, O. TURGAK (*Eskisehir, Turkey*) ... 209


**Clinical Studies**

Prevalence of Neurotropic Viruses in Malignant Glioma and Their Onco-Modulatory Potential. T. STROJNIK, D. DUH, T.T. LAH (*Maribor; Ljubljana, Slovenia*) ................................................................. 221

Mild Versus Conventional Ovarian Stimulation for Poor Responders Undergoing IVF/ICSI: A Prospective Randomized Study. C. SIRISTATIDIS, G. SALAMALEKIS, K. DAFOPOULOS, G. BASIOS, P. VOGIATZI, N. PAPANTONIOU (*Athens; Larissa, Greece*) ................................................................. 231

Chemoradiation Including Paclitaxel for Locally Recurrent Muscle-invasive Bladder Cancer in Elderly Patients. L. KÄSMANN, L. MANIG, S. JANSSEN, D. RADES (*Lübeck, Germany*) ................................................................. 239

Polymorphisms of Platelet Glycoprotein Receptors and Cell Adhesion Molecules in Fetuses with Fetal Growth Restriction and Their Mothers As Detected with Pyrosequencing. M. SIMOU, E. KOUSKOUNI, N. VITORATOS, E. ECONOMOU, G. CREATSAS (*Athens, Greece*) ................................................................. 243

Improvement of Perioperative Outcomes in Major Gynecological and Gynecologic–Oncological Surgery with Hemostatic Gelatin–Thrombin Matrix. R. WATROWSKI, C. JÄGER, J. FORSTER (*Freiburg, Germany*) ................................................................. 251

Lack of Definite Association of Vitamin D Deficiency with Diabetic Neuropathy. Investigation in Greek and in Bangladeshi Patients. T. ZAMBELIS, G. PAPADAKIS, P. KOKOTIS, V. VILLIOTOU, N. DOGKAS, N. KARANDREAS (*Athens; Piraeus, Greece*) ................................................................. 259

Sclerotherapy for Orbital Lymphangioma – Case Series and Literature Review. K.C. PATEL, G. KALANTZIS, N. EL-HINDY, B.Y. CHANG (*Huddersfield; Leeds, UK*) ................................................................. 263